retatrutide science – Today, we shared new data

When you eat too quickly, your body misses the chance to send those fullness signals

Retatrutide is an investigational GIP, GLP-1, and glucagon triple receptor agonist not yet approved by the MHRA or EMA

However, a slight numerical increase in suicidal ideation was observed among liraglutide recipients, with nine cases (0.3%) in the liraglutide group compared to two cases (0.1%) in the placebo group [71]

West Pharmaceutical provides elastomer stoppers for pens

Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/beta-endorphin pathway

In the original Phase 2 study, about 71% of patients in the 0.5 mg arm completed the 24-week treatment and roughly 20% withdrew due to adverse events